Cargando…

Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study

Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates insulin-like growth factor-I (IGF-I) bioactivity, and is a central player in normal growth, metabolism, and stroke recovery. However, the role of serum IGFBP-1 (s-IGFBP-1) after ischemic stroke is unclear. We determined whether s-IGFBP...

Descripción completa

Detalles Bibliográficos
Autores principales: Åberg, Daniel, Gadd, Gustaf, Jood, Katarina, Redfors, Petra, Stanne, Tara M., Isgaard, Jörgen, Blennow, Kaj, Zetterberg, Henrik, Jern, Christina, Åberg, N. David, Svensson, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252273/
https://www.ncbi.nlm.nih.gov/pubmed/37298072
http://dx.doi.org/10.3390/ijms24119120
_version_ 1785056130525822976
author Åberg, Daniel
Gadd, Gustaf
Jood, Katarina
Redfors, Petra
Stanne, Tara M.
Isgaard, Jörgen
Blennow, Kaj
Zetterberg, Henrik
Jern, Christina
Åberg, N. David
Svensson, Johan
author_facet Åberg, Daniel
Gadd, Gustaf
Jood, Katarina
Redfors, Petra
Stanne, Tara M.
Isgaard, Jörgen
Blennow, Kaj
Zetterberg, Henrik
Jern, Christina
Åberg, N. David
Svensson, Johan
author_sort Åberg, Daniel
collection PubMed
description Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates insulin-like growth factor-I (IGF-I) bioactivity, and is a central player in normal growth, metabolism, and stroke recovery. However, the role of serum IGFBP-1 (s-IGFBP-1) after ischemic stroke is unclear. We determined whether s-IGFBP-1 is predictive of poststroke outcome. The study population comprised patients (n = 470) and controls (n = 471) from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS). Functional outcome was evaluated after 3 months, 2, and 7 years using the modified Rankin Scale (mRS). Survival was followed for a minimum of 7 years or until death. S-IGFBP-1 was increased after 3 months (p < 0.01), but not in the acute phase after stroke, compared with the controls. Higher acute s-IGFBP-1 was associated with poor functional outcome (mRS score > 2) after 7 years [fully adjusted odds ratio (OR) per log increase 2.9, 95% confidence interval (CI): 1.4-5.9]. Moreover, higher s-IGFBP-1 after 3 months was associated with a risk of poor functional outcome after 2 and 7 years (fully adjusted: OR 3.4, 95% CI: 1.4–8.5 and OR 5.7, 95% CI: 2.5–12.8, respectively) and with increased mortality risk (fully adjusted: HR 2.0, 95% CI: 1.1–3.7). Thus, high acute s-IGFBP-1 was only associated with poor functional outcome after 7 years, whereas s-IGFBP-1 after 3 months was an independent predictor of poor long-term functional outcome and poststroke mortality.
format Online
Article
Text
id pubmed-10252273
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102522732023-06-10 Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study Åberg, Daniel Gadd, Gustaf Jood, Katarina Redfors, Petra Stanne, Tara M. Isgaard, Jörgen Blennow, Kaj Zetterberg, Henrik Jern, Christina Åberg, N. David Svensson, Johan Int J Mol Sci Article Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates insulin-like growth factor-I (IGF-I) bioactivity, and is a central player in normal growth, metabolism, and stroke recovery. However, the role of serum IGFBP-1 (s-IGFBP-1) after ischemic stroke is unclear. We determined whether s-IGFBP-1 is predictive of poststroke outcome. The study population comprised patients (n = 470) and controls (n = 471) from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS). Functional outcome was evaluated after 3 months, 2, and 7 years using the modified Rankin Scale (mRS). Survival was followed for a minimum of 7 years or until death. S-IGFBP-1 was increased after 3 months (p < 0.01), but not in the acute phase after stroke, compared with the controls. Higher acute s-IGFBP-1 was associated with poor functional outcome (mRS score > 2) after 7 years [fully adjusted odds ratio (OR) per log increase 2.9, 95% confidence interval (CI): 1.4-5.9]. Moreover, higher s-IGFBP-1 after 3 months was associated with a risk of poor functional outcome after 2 and 7 years (fully adjusted: OR 3.4, 95% CI: 1.4–8.5 and OR 5.7, 95% CI: 2.5–12.8, respectively) and with increased mortality risk (fully adjusted: HR 2.0, 95% CI: 1.1–3.7). Thus, high acute s-IGFBP-1 was only associated with poor functional outcome after 7 years, whereas s-IGFBP-1 after 3 months was an independent predictor of poor long-term functional outcome and poststroke mortality. MDPI 2023-05-23 /pmc/articles/PMC10252273/ /pubmed/37298072 http://dx.doi.org/10.3390/ijms24119120 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Åberg, Daniel
Gadd, Gustaf
Jood, Katarina
Redfors, Petra
Stanne, Tara M.
Isgaard, Jörgen
Blennow, Kaj
Zetterberg, Henrik
Jern, Christina
Åberg, N. David
Svensson, Johan
Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study
title Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study
title_full Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study
title_fullStr Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study
title_full_unstemmed Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study
title_short Serum IGFBP-1 Concentration as a Predictor of Outcome after Ischemic Stroke—A Prospective Observational Study
title_sort serum igfbp-1 concentration as a predictor of outcome after ischemic stroke—a prospective observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252273/
https://www.ncbi.nlm.nih.gov/pubmed/37298072
http://dx.doi.org/10.3390/ijms24119120
work_keys_str_mv AT abergdaniel serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT gaddgustaf serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT joodkatarina serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT redforspetra serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT stannetaram serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT isgaardjorgen serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT blennowkaj serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT zetterberghenrik serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT jernchristina serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT abergndavid serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy
AT svenssonjohan serumigfbp1concentrationasapredictorofoutcomeafterischemicstrokeaprospectiveobservationalstudy